CA2182686A1 - Agent for marking bodily tissues - Google Patents
Agent for marking bodily tissuesInfo
- Publication number
- CA2182686A1 CA2182686A1 CA002182686A CA2182686A CA2182686A1 CA 2182686 A1 CA2182686 A1 CA 2182686A1 CA 002182686 A CA002182686 A CA 002182686A CA 2182686 A CA2182686 A CA 2182686A CA 2182686 A1 CA2182686 A1 CA 2182686A1
- Authority
- CA
- Canada
- Prior art keywords
- marking
- colored
- bodily tissues
- dye
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000126 substance Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000002872 contrast media Substances 0.000 claims description 17
- 229940039231 contrast media Drugs 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 8
- 239000011859 microparticle Substances 0.000 claims description 7
- 230000005291 magnetic effect Effects 0.000 claims description 6
- 150000004032 porphyrins Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 16
- 210000001519 tissue Anatomy 0.000 description 40
- 239000000975 dye Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 229960000907 methylthioninium chloride Drugs 0.000 description 6
- 238000003325 tomography Methods 0.000 description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002845 discoloration Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000009607 mammography Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XBBVURRQGJPTHH-DKWTVANSSA-N 2-hydroxyacetic acid;(2s)-2-hydroxypropanoic acid Chemical compound OCC(O)=O.C[C@H](O)C(O)=O XBBVURRQGJPTHH-DKWTVANSSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OEURTUVCLQKUCB-UHFFFAOYSA-K CC([O-])=O.[O-]C(COC1=CC=CC(C(C2=CC=C(C(C3=CC(OCC([O-])=O)=CC=C3)=C3N=C4C=C3)N2)=C(C=C2)N=C2C(C2=CC(OCC(O)=O)=CC=C2)=C(C=C2)NC2=C4C2=CC(OCC(O)=O)=CC=C2)=C1)=O.[Mn+3] Chemical compound CC([O-])=O.[O-]C(COC1=CC=CC(C(C2=CC=C(C(C3=CC(OCC([O-])=O)=CC=C3)=C3N=C4C=C3)N2)=C(C=C2)N=C2C(C2=CC(OCC(O)=O)=CC=C2)=C(C=C2)NC2=C4C2=CC(OCC(O)=O)=CC=C2)=C1)=O.[Mn+3] OEURTUVCLQKUCB-UHFFFAOYSA-K 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- -1 e.g. Inorganic materials 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960003988 indigo carmine Drugs 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3933—Liquid markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3937—Visible markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3954—Markers, e.g. radio-opaque or breast lesions markers magnetic, e.g. NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
Abstract
The invention relates to the use of colored NMR-, x-ray- or optionally dye-containing ultrasonic-imaging substances for marking bodily tissues.
Description
2 1 ~2~)Q,6 Agent for Visually Marking Bodily Tissues The invention relates to the object characterized in the claims, i.e., the use of colored NMR or x-ray contrast media or of optionally dye-containing ultrasonic contrast media for the production of a diagnostic agent for visually marking bodily tissues.
With increasing refinement of radiological imaging, increasingly smaller changes are detected which in some cases to a surgeon are not reliably palpable either in clinical examination or during surgery. Thus, structures up to 1 mm3 can be made visible. Such changes can also be difficult for pathologists to find since, for reasons of time and money, the very expensive millimeter-by-millimeter working-up of major tissues is generally not possible. This is especially important when minor malignant growths are detected in early stages of malignant growths, such as in-situ carcinomas (which almost routinely are not palpable), and for detecting reliable excision in the case of radiologically unclear changes, where there may be no histologic indication of a malignant growth. As examples of changes that must be marked pre-operatively, there can be mentioned: nonpalpable suspect changes that are found during mammographic screening or small subpleural changes that must be excised to rule out or detect metastasis in order to decide on a course of treatment in patients with sarcomas or testicular tumors.
21 ~2686 To ensure that such changes are found without unnecessary traumatization or removal of sizeable healthy surrounding tissue and to ensure reliable correlation with the histopathologic findings tincluding for forensic purposes), such changes must be marked pre-operatively under so-called x-ray, ultrasonic, computer-tomographic, or nuclear-spin-tomographic control.
For radiologically controlled marking of tissues -- after visualization of the lesion with the corresponding radiologic process -- mainly the following techniques have been used to date:
1. Marking of the skin overlying the tissue by an object or by dye.
2. A needle or wire (generally with a way to anchor it) is directed to the focus and left in place until surgery is performed.
With increasing refinement of radiological imaging, increasingly smaller changes are detected which in some cases to a surgeon are not reliably palpable either in clinical examination or during surgery. Thus, structures up to 1 mm3 can be made visible. Such changes can also be difficult for pathologists to find since, for reasons of time and money, the very expensive millimeter-by-millimeter working-up of major tissues is generally not possible. This is especially important when minor malignant growths are detected in early stages of malignant growths, such as in-situ carcinomas (which almost routinely are not palpable), and for detecting reliable excision in the case of radiologically unclear changes, where there may be no histologic indication of a malignant growth. As examples of changes that must be marked pre-operatively, there can be mentioned: nonpalpable suspect changes that are found during mammographic screening or small subpleural changes that must be excised to rule out or detect metastasis in order to decide on a course of treatment in patients with sarcomas or testicular tumors.
21 ~2686 To ensure that such changes are found without unnecessary traumatization or removal of sizeable healthy surrounding tissue and to ensure reliable correlation with the histopathologic findings tincluding for forensic purposes), such changes must be marked pre-operatively under so-called x-ray, ultrasonic, computer-tomographic, or nuclear-spin-tomographic control.
For radiologically controlled marking of tissues -- after visualization of the lesion with the corresponding radiologic process -- mainly the following techniques have been used to date:
1. Marking of the skin overlying the tissue by an object or by dye.
2. A needle or wire (generally with a way to anchor it) is directed to the focus and left in place until surgery is performed.
3. The tissue to be excised is marked directly by injecting a dye.
The above-mentioned techniques are associated with various drawbacks, however. Thus, method 1 is inaccurate in the case of lesions in subjacent tissue, especially in the case of tissue with considerable respiratory mobility (e.g., breast cancer).
Method 2 overcomes this drawback, but this is offset by an increased risk of infection, especially if there is an extended period between diagnosis and surgery. It is uncomfortable for the patient, and in addition, there exists the danger of dislocation despite anchoring, as well as the danger of coming off during surgery and thus leaving a sharp foreign object in the Zl ~2686 tissue [A. W. M. C. Owen and E. Nanda Kumar: Migration of Localizing Wires Used in Guided Biopsy of the Breast. Clin.
Radiology (1991) 43, 251. J. B. Bristol, Jones P. A.:
Transgression of a Localizing Wire into the Pleural Cavity Prior to Mammography. Br. J. of Radiology (1981) 54, 139-140. L. S.
Gormly, L. W. Bassett: Pre-biopsy Needle Localizing, Ductography and Pneumocystography. In: Mitchell, G. W.; Bassett, L. W.:
(eds): The Female Breast and its Disorders. Baltimore, Williams and Wilkins, 1990].
The most frequently used method at this time is method 3.
Generally, in this case, an injection needle is inserted directly into the focus while being monitored by x-ray, and the appropriate dye is injected. In this case, however -- especially in the case of small lesions -- it is not ensured that the dye has actually been injected into the lesion. Thus, it often happens that the die is injected right next to the focus. To locate the retention site of the dye exactly, the latter is therefore generally mixed with a contrast medium (NMR, x-ray), which can be readily detected in a corresponding imaging process, and the exact position of the dye also can be deduced from its spatial position. As dyes for marking tissues, on the one hand, to date water-soluble dyes, such as indigo carmine or methylene blue, etc., or non-soluble substances, such as suspended sterile activated carbon, have been used.
Water-soluble dyes have -- apart from a few allergic reactions -- the advantage of acceptable compatibility. They are readily visible to surgeons and are completely excreted. Their 21 826~6 main drawback is that they diffuse into tissue very quickly.
Even in the case of a relatively short interval (even as little as 1-2 hours) between radiological marking and surgery, the dye spreads quickly into the surrounding area, so that large areas are stained, and exact detection is then no longer possible.
The sterile activated carbon that is suspended in physiological common salt solution, however, remains, for the most part, at the injection site until the operating surgeon removes it. This considerably facilitates scheduling between radiological marking and, e.g., a routine operation. In addition, an exact histopathologic correlation is generally possible without difficulty with good marking. Drawbacks of activated carbon include, however, the fact that the latter cannot be excreted from the body and can lead to reactive changes in the tissue or in draining lymph nodes. In addition, fine-particulate activated carbon also tends to lump up -- possibly due to electrostatic effects. This is a considerable drawback since needles of up to 18 gauge frequently clog and thus remarking with a new needle must be performed.
The object of this invention is therefore to provide a marking agent that overcomes the drawbacks of the prior art, i.e., to find a marking agent that 1. is well-tolerated, 2. exhibits immobility in the tissue over a sufficiently long period, 3. can be detected both visually and radiologically in the tissue in question, and that 4. is readily injectable through long and thin cannulae.
The object is achieved by the invention.
It has been found that black or colored contrast media are suitable for magnetic resonance tomography or diagnostic radiology, as well as gas-/dye- or gas-containing microparticles, such as are suitable for ultrasonic diagnosis, which readily meet the above-mentioned requirements, surprisingly enough, and are therefore extremely well suited for visually marking bodily tissues for the purpose of subsequent detection of such tissues.
The invention thus pertains to the use of colored NMR or x-ray contrast media or of optionally dye-containing ultrasonic contrast media for the production of a diagnostic agent for visually marking bodily tissues.
Examples of such agents are mentioned below.
Suitable are, e.g., suspensions of magnetites, i.e., colloidal solutions or mixtures of FeO and Fe203 that are stabilized by a more or less hydrophilic coating with generally organic molecules. Because of their strong effect on the relaxation of protons or owing to their x-ray-absorbing action, the latter show not only an imaging effect in radiological processes, they are also readily visually detectable because of their dark brown to black colors, so that they are especially well suited for marking light tissues (e.g., fat, glandular tissue, muscle, connective tissue). Although magnetites almost always have diameters of far below 1 ~m and are readily suspendable in water and thus transportable, they remain largely undiluted at the injection site for a surprisingly long time - 2~ 826(3~
(days to months) after injection into the tissue, and they are readily visible there to the eye. Magnetites are locally well-tolerated. Iron oxides are dissolved on a long-term basis, and iron is converted in natural iron metabolism.
In addition, marking with magnetites opens up the possibility of dyeing in histologic sections the iron that is contained in the magnetites with potassium rhodanide as "Berlin blue."
Magnetites that are suitable for medical use and processes for their production are described, e.g., in US 4,731,239, US
4,770,183, US 4,827,945, US 4,767,611, EP 0 186 616, SE 83 070 60, SE 84 054 99, GB 84-08127, DE 35 79 899, W0 91/05807.
In addition to magnetites, metal porphyrins are also suitable for the above-indicated purpose. The latter can be readily detected, depending on the metal contained, either by radiography or, if these are paramagnetic metal ions, such as, e.g., Fe3+, manganese3~, gadolinium3', etc. in the complexed metals, with the aid of magnetic resonance tomography. In addition, porphyrins absorb light in the visible frequency range, so that they can also be readily detected visually. Especially suitable are intensively colored complexes, as they are described, e.g., in EP 0 336 879 or EP 0 355 041.
Further suitable are ultrasonic contrast media that also contain a dye in addition to the encapsulated echoing gas. Such contrast media are described in DE 43 30 958. As dyes, basically all physiologically compatible dyes, such as, e.g., hemoglobin, chlorophyll, etc., are suitable. Suitable also, however, are 7 2 1 8268~
those dyes which would quickly diffuse in unencapsulated form (such as, e.g., methylene blue). Encapsulation prevents diffusion, i.e., the dye remains at the injection site and can be released there only just before surgery, as described in DE 43 30 958, by irradiation of ultrasound of suitable frequency and wavelength.
Since ultrasonic devices are available in any operating room, the release of dye can even be done by surgeons in the operating room. Extensive dispersion of dye is largely avoided because of the brevity of the period between the release of dye and the visual redetection of the marked points even in the case of water-soluble dyes that diffuse quickly.
Other particles that can be detected by ultrasound, such as are described, e.g., in US 4,276,885, EP O 327 490, EP 0 458 079 and EP O 535 387, are also suitable for marking.
In addition, various fairly non-toxic dyes that can be detected in the body by imaging processes that are commonly used, such as, e.g., melanin or various stable radicals that influence the relaxation times of tissues and therefore result in an imaging effect in nuclear spin tomography, are suitable.
Examples of such radicals include [G. Sosnovsky, A Critical Evaluation of the Present Status of Toxicity of Aminoxyl Radicals, J. Pharmaceut. Sci. 81 (1992) 496-499].
The previously mentioned agents are extremely well suited for marking tissues, especially in regions of the body that are not accessible to direct visual inspection. Surprisingly enough, they are also stable in place over a prolonged period, i.e., they 21 8268~
do not diffuse during the interval of time between marking and surgery or diffuse negligibly slowly. The above-mentioned agents are well-tolerated and visually detectable, surprisingly enough, even at very low concentrations while still being usable in imaging radiological processes. As a result, with a dose to be administered in an injection it is possible both to prepare a control picture with an imaging process [such as, e.g., radiotechnology including conventional x-ray pictures, such as, e.g., mammography or computer tomography, magnetic resonance tomography (MRT) as well as ultrasound methods], and to produce a marking that is readily discernible to surgeons.
The above-mentioned agents are thus of special value in the marking of small tissue areas that lie one or more centimeters below the body surface area, especially if the latter -- owing to their position in soft tissue -- can easily slide in the case of movement (e.g., breast tissue, testicular tissue).
They are also especially suitable for marking the spot of the tissue sample that is removed before the surgical intervention (under the control of the mentioned imaging processes) using a biopsy needle. Without such a marking, this spot could not be found again in a surgical intervention that may be necessary later after the needle is pulled out.
In addition, especially in the case of small lesions, the difficulty of placing the biopsy needle exactly often exists, so that not suspect tissue -- as presumed -- but rather surrounding healthy tissue is removed, which necessarily results in a false pathological finding. If the above-mentioned agent is injected, 21 826~
however, immediately after the removal of the sample via the same cannula, it can be readily discerned in the corresponding imaging process whether the sample was actually removed at the intended spot.
According to the invention, the above-mentioned agents are generally introduced via a fairly long cannula as a solution, suspension or emulsion, while being observed visually in the above-mentioned imaging processes in the corresponding tissue region. If the imaging process used is nuclear spin tomography, cannulas that consist of non-magnetic material are to be used, of course, because of the strong magnetic fields. Owing to the imaging properties of the administered agent, a control picture can be produced immediately after administration which will show whether the marking was actually placed at the desired spot.
Also, if the lesion was missed, the operating surgeon can easily find the tumor region again based on the color marking since the relative position of the tumor region in the color marking can be easily ascertained from the control picture.
As already mentioned, the above-mentioned agents are generally readily visible to the naked eye. In the case of ultrasonic contrast media based on gaseous microparticles, it is advisable, however (because of the insignificant marking caused by the particles), to redetect particles with an ultrasonic scanner instead of visual inspection. Such devices are available in any operating room (unlike a nuclear spin tomograph or an x-ray device).
~ 1 ~ 2 6 1~ rl In the case of some marking agents, such as, e.g., porphyrins, it is advisable to enhance the chromophoric effect by stimulation with infrared or ultraviolet light. Also, the additives required for this are readily available in any operating room.
All preparations that are provided for injection into tissue must be absolutely sterile. They may optionally contain the pharmaceutical adjuvants that are commonly used for isotonizing (e.g., glucose, NaCl), buffering or stabilizing the solution or emulsion or suspension.
The dose administered depends primarily on the size of the tissue area to be marked. It may be very small at 50 ~l.
Injection volumes of 0.1 to 2 ml are preferred. In the case of sizeable or multifocal processes, it can be necessary to inject up to 5 or more milliliters of marking agent. In the case of low volumes, higher concentrations of the individual components are preferred; in the case of higher volumes, smaller concentrations are more likely to be used in order to avoid, among other things, artifacts in the imaging diagnosis.
The concentrations of the agents administered vary depending on the imaging processes selected in each case.
Thus, opacifying substances for magnetic resonance tomography are used at concentrations of 0.1-100 ~mol/ml, preferably 1-20 ~mol/ml, x-ray-opacifying agents are used in the range of 3-100 mg of opacifying elements (e.g., iodine, iron, etc.)/ml and ultrasonic-opacifying preparations in the range of 0.01 to 50 ~l of gas/ml, preferably 0.1 to 5 ~l of gas/ml.
Magnetites are also used as aqueous solutions with about 0.1 ~mol of iron/ml to 500 ~mol of iron/ml. Strongly colored solutions with about 20-500 ~mol of iron/ml are preferred.
Metalloporphyrins are used in the same concentration range (0.1 ~mol/ml - 500 ~mol/ml), whereby the preferred range is approximately 20-200 ~mol/ml.
Other paramagnetic or metal ion-containing or iodine-containing dyes, such as, e.g., Bengal pink, erythrosin, tetrachlorotetraiodine fluorescein, are preferably used at somewhat higher concentrations (50-500 ~mol/ml).
The above-indicated concentrations are to be considered as guideline values; individual cases may exceed or fall below these guideline values. They are sufficient to produce a clear imaging effect and at the same time a visually discernible marking of the tissue in the respective radiological process.
The following examples are used to explain the object of the invention, without intending that they be limited to this object.
21 826(`3~-~
Example 1 Marking of a Biopsy Area with Magnetites A suspect tissue region is identified in MRT. To study tumorous tissue, a needle biopsy is performed, in which cells are obtained from the corresponding area. To control the exact position of the needle as well as to facilitate finding the appropriate tissue region again in the case of a subsequent operation, 0.5 ml of a 50 mmol dextran-magnetite solution (SH U
555, Schering AG, Berlin) is injected. After the solution is injected, the appropriate area in the MRT represents a signal alarm. In the laying-open during surgery, the biopsy area can be discerned from the brownish discoloration. In the same way, the pathologist can get his bearings in the surgery and apply the necessary sections in the proper plane.
Example 2 Marking of a 8iopsy Area with Porphyrins The procedure is as described in Example 1. As a marking solution, however, 2 ~mol of manganese (as manganese(III) {tetrakis-[3-(carboxylatomethoxy)-phenyl]-porphyrin}-acetate complex) is injected in a milliliter of physiological common salt solution. In the laying-open during surgery, the biopsy area can be discerned from the yellow-greenish discoloration. The color effect can be additionally enhanced by short-term stimulation with W light.
Example 3 Marking of a Breast Cancer with Magnetites During mammography, microcalcifications are found at a volume of less than 0.5 cm3. The region is stereotactically biopsied. At the same time, 0.2 ml of 500 mmol magnetite solution is injected. The biopsy reveals a breast cancer. The identification of the lesion during surgery is facilitated by the clear black-brown discoloration.
Example 4 Marking of Muscle Tissue with Magnetites The dextran-magnetite solution (SH U 555, Schering AG) is injected at a concentration of A) 500 mmol of Fe/liter, B) 250 mmol of Fe/liter, C) 125 mmol of Fe/liter and a dose of 1 ml in muscle tissue and examined by computer tomography. The magnetite depot is clearly discernible in all cases and strictly limited in shape. After the corresponding tissue region is laid open, the magnetite is optically readily discernible from the brownish discoloration.
Example 5 Methylene blue-containing microparticles that consist of poly(D,L-lactic acid-glycolic acid) are irradiated in vitro in a tissue sample with ultrasound (sonic pressure > 50 dB, frequency 2.5 Mhz), and in this process methylene blue is released in the tissue.
The methylene blue-containing particles can be produced as disclosed in DE 43 30 958 (Example 8), by 4 g of poly(D,L-lactic acid-glycolic acid) (50:50) (Resomer RG 503, Boehringer Ingelheim), dissolved in 50 ml of CH2Cl2, being emulsified with 20 mg of methylene blue, dissolved in 4 ml of aqueous 4% gelatin solution, while being stirred with a fast stirrer. Then, another 21 826~6 200 ml of a 4% autoclaved gelatin solution is added. The emulsion is stirred for 8 hours at room temperature. The particles that are produced are filtered by a 5 ~m filter, separated by centrifuging, resuspended in S0 ml of 4% autoclaved gelatin solution, frozen at -78C, and freeze-dried. After resuspension, the gaseous microparticles are separated by centrifuging (at 1000 rpm, 30 min). The particles thus obtained are taken up in 20 ml of water for injection purposes and can be used directly for marking bodily tissue.
Ex~mple 6 0.05 ml of a suspension of gas-filled hollow bodies with a shell made of biodegradable poly-2-cyanoacrylic acid butyl ester (W093/25242; Example 1) and an average particle size of about 2 ~m is injected into the musculature of the upper leg of a dog.
3.5 hours later, a strictly limited depot of contrast medium, which can be readily located in all planes, is found in the ultrasonic study with a 3.5 MHz transducer.
The above-mentioned techniques are associated with various drawbacks, however. Thus, method 1 is inaccurate in the case of lesions in subjacent tissue, especially in the case of tissue with considerable respiratory mobility (e.g., breast cancer).
Method 2 overcomes this drawback, but this is offset by an increased risk of infection, especially if there is an extended period between diagnosis and surgery. It is uncomfortable for the patient, and in addition, there exists the danger of dislocation despite anchoring, as well as the danger of coming off during surgery and thus leaving a sharp foreign object in the Zl ~2686 tissue [A. W. M. C. Owen and E. Nanda Kumar: Migration of Localizing Wires Used in Guided Biopsy of the Breast. Clin.
Radiology (1991) 43, 251. J. B. Bristol, Jones P. A.:
Transgression of a Localizing Wire into the Pleural Cavity Prior to Mammography. Br. J. of Radiology (1981) 54, 139-140. L. S.
Gormly, L. W. Bassett: Pre-biopsy Needle Localizing, Ductography and Pneumocystography. In: Mitchell, G. W.; Bassett, L. W.:
(eds): The Female Breast and its Disorders. Baltimore, Williams and Wilkins, 1990].
The most frequently used method at this time is method 3.
Generally, in this case, an injection needle is inserted directly into the focus while being monitored by x-ray, and the appropriate dye is injected. In this case, however -- especially in the case of small lesions -- it is not ensured that the dye has actually been injected into the lesion. Thus, it often happens that the die is injected right next to the focus. To locate the retention site of the dye exactly, the latter is therefore generally mixed with a contrast medium (NMR, x-ray), which can be readily detected in a corresponding imaging process, and the exact position of the dye also can be deduced from its spatial position. As dyes for marking tissues, on the one hand, to date water-soluble dyes, such as indigo carmine or methylene blue, etc., or non-soluble substances, such as suspended sterile activated carbon, have been used.
Water-soluble dyes have -- apart from a few allergic reactions -- the advantage of acceptable compatibility. They are readily visible to surgeons and are completely excreted. Their 21 826~6 main drawback is that they diffuse into tissue very quickly.
Even in the case of a relatively short interval (even as little as 1-2 hours) between radiological marking and surgery, the dye spreads quickly into the surrounding area, so that large areas are stained, and exact detection is then no longer possible.
The sterile activated carbon that is suspended in physiological common salt solution, however, remains, for the most part, at the injection site until the operating surgeon removes it. This considerably facilitates scheduling between radiological marking and, e.g., a routine operation. In addition, an exact histopathologic correlation is generally possible without difficulty with good marking. Drawbacks of activated carbon include, however, the fact that the latter cannot be excreted from the body and can lead to reactive changes in the tissue or in draining lymph nodes. In addition, fine-particulate activated carbon also tends to lump up -- possibly due to electrostatic effects. This is a considerable drawback since needles of up to 18 gauge frequently clog and thus remarking with a new needle must be performed.
The object of this invention is therefore to provide a marking agent that overcomes the drawbacks of the prior art, i.e., to find a marking agent that 1. is well-tolerated, 2. exhibits immobility in the tissue over a sufficiently long period, 3. can be detected both visually and radiologically in the tissue in question, and that 4. is readily injectable through long and thin cannulae.
The object is achieved by the invention.
It has been found that black or colored contrast media are suitable for magnetic resonance tomography or diagnostic radiology, as well as gas-/dye- or gas-containing microparticles, such as are suitable for ultrasonic diagnosis, which readily meet the above-mentioned requirements, surprisingly enough, and are therefore extremely well suited for visually marking bodily tissues for the purpose of subsequent detection of such tissues.
The invention thus pertains to the use of colored NMR or x-ray contrast media or of optionally dye-containing ultrasonic contrast media for the production of a diagnostic agent for visually marking bodily tissues.
Examples of such agents are mentioned below.
Suitable are, e.g., suspensions of magnetites, i.e., colloidal solutions or mixtures of FeO and Fe203 that are stabilized by a more or less hydrophilic coating with generally organic molecules. Because of their strong effect on the relaxation of protons or owing to their x-ray-absorbing action, the latter show not only an imaging effect in radiological processes, they are also readily visually detectable because of their dark brown to black colors, so that they are especially well suited for marking light tissues (e.g., fat, glandular tissue, muscle, connective tissue). Although magnetites almost always have diameters of far below 1 ~m and are readily suspendable in water and thus transportable, they remain largely undiluted at the injection site for a surprisingly long time - 2~ 826(3~
(days to months) after injection into the tissue, and they are readily visible there to the eye. Magnetites are locally well-tolerated. Iron oxides are dissolved on a long-term basis, and iron is converted in natural iron metabolism.
In addition, marking with magnetites opens up the possibility of dyeing in histologic sections the iron that is contained in the magnetites with potassium rhodanide as "Berlin blue."
Magnetites that are suitable for medical use and processes for their production are described, e.g., in US 4,731,239, US
4,770,183, US 4,827,945, US 4,767,611, EP 0 186 616, SE 83 070 60, SE 84 054 99, GB 84-08127, DE 35 79 899, W0 91/05807.
In addition to magnetites, metal porphyrins are also suitable for the above-indicated purpose. The latter can be readily detected, depending on the metal contained, either by radiography or, if these are paramagnetic metal ions, such as, e.g., Fe3+, manganese3~, gadolinium3', etc. in the complexed metals, with the aid of magnetic resonance tomography. In addition, porphyrins absorb light in the visible frequency range, so that they can also be readily detected visually. Especially suitable are intensively colored complexes, as they are described, e.g., in EP 0 336 879 or EP 0 355 041.
Further suitable are ultrasonic contrast media that also contain a dye in addition to the encapsulated echoing gas. Such contrast media are described in DE 43 30 958. As dyes, basically all physiologically compatible dyes, such as, e.g., hemoglobin, chlorophyll, etc., are suitable. Suitable also, however, are 7 2 1 8268~
those dyes which would quickly diffuse in unencapsulated form (such as, e.g., methylene blue). Encapsulation prevents diffusion, i.e., the dye remains at the injection site and can be released there only just before surgery, as described in DE 43 30 958, by irradiation of ultrasound of suitable frequency and wavelength.
Since ultrasonic devices are available in any operating room, the release of dye can even be done by surgeons in the operating room. Extensive dispersion of dye is largely avoided because of the brevity of the period between the release of dye and the visual redetection of the marked points even in the case of water-soluble dyes that diffuse quickly.
Other particles that can be detected by ultrasound, such as are described, e.g., in US 4,276,885, EP O 327 490, EP 0 458 079 and EP O 535 387, are also suitable for marking.
In addition, various fairly non-toxic dyes that can be detected in the body by imaging processes that are commonly used, such as, e.g., melanin or various stable radicals that influence the relaxation times of tissues and therefore result in an imaging effect in nuclear spin tomography, are suitable.
Examples of such radicals include [G. Sosnovsky, A Critical Evaluation of the Present Status of Toxicity of Aminoxyl Radicals, J. Pharmaceut. Sci. 81 (1992) 496-499].
The previously mentioned agents are extremely well suited for marking tissues, especially in regions of the body that are not accessible to direct visual inspection. Surprisingly enough, they are also stable in place over a prolonged period, i.e., they 21 8268~
do not diffuse during the interval of time between marking and surgery or diffuse negligibly slowly. The above-mentioned agents are well-tolerated and visually detectable, surprisingly enough, even at very low concentrations while still being usable in imaging radiological processes. As a result, with a dose to be administered in an injection it is possible both to prepare a control picture with an imaging process [such as, e.g., radiotechnology including conventional x-ray pictures, such as, e.g., mammography or computer tomography, magnetic resonance tomography (MRT) as well as ultrasound methods], and to produce a marking that is readily discernible to surgeons.
The above-mentioned agents are thus of special value in the marking of small tissue areas that lie one or more centimeters below the body surface area, especially if the latter -- owing to their position in soft tissue -- can easily slide in the case of movement (e.g., breast tissue, testicular tissue).
They are also especially suitable for marking the spot of the tissue sample that is removed before the surgical intervention (under the control of the mentioned imaging processes) using a biopsy needle. Without such a marking, this spot could not be found again in a surgical intervention that may be necessary later after the needle is pulled out.
In addition, especially in the case of small lesions, the difficulty of placing the biopsy needle exactly often exists, so that not suspect tissue -- as presumed -- but rather surrounding healthy tissue is removed, which necessarily results in a false pathological finding. If the above-mentioned agent is injected, 21 826~
however, immediately after the removal of the sample via the same cannula, it can be readily discerned in the corresponding imaging process whether the sample was actually removed at the intended spot.
According to the invention, the above-mentioned agents are generally introduced via a fairly long cannula as a solution, suspension or emulsion, while being observed visually in the above-mentioned imaging processes in the corresponding tissue region. If the imaging process used is nuclear spin tomography, cannulas that consist of non-magnetic material are to be used, of course, because of the strong magnetic fields. Owing to the imaging properties of the administered agent, a control picture can be produced immediately after administration which will show whether the marking was actually placed at the desired spot.
Also, if the lesion was missed, the operating surgeon can easily find the tumor region again based on the color marking since the relative position of the tumor region in the color marking can be easily ascertained from the control picture.
As already mentioned, the above-mentioned agents are generally readily visible to the naked eye. In the case of ultrasonic contrast media based on gaseous microparticles, it is advisable, however (because of the insignificant marking caused by the particles), to redetect particles with an ultrasonic scanner instead of visual inspection. Such devices are available in any operating room (unlike a nuclear spin tomograph or an x-ray device).
~ 1 ~ 2 6 1~ rl In the case of some marking agents, such as, e.g., porphyrins, it is advisable to enhance the chromophoric effect by stimulation with infrared or ultraviolet light. Also, the additives required for this are readily available in any operating room.
All preparations that are provided for injection into tissue must be absolutely sterile. They may optionally contain the pharmaceutical adjuvants that are commonly used for isotonizing (e.g., glucose, NaCl), buffering or stabilizing the solution or emulsion or suspension.
The dose administered depends primarily on the size of the tissue area to be marked. It may be very small at 50 ~l.
Injection volumes of 0.1 to 2 ml are preferred. In the case of sizeable or multifocal processes, it can be necessary to inject up to 5 or more milliliters of marking agent. In the case of low volumes, higher concentrations of the individual components are preferred; in the case of higher volumes, smaller concentrations are more likely to be used in order to avoid, among other things, artifacts in the imaging diagnosis.
The concentrations of the agents administered vary depending on the imaging processes selected in each case.
Thus, opacifying substances for magnetic resonance tomography are used at concentrations of 0.1-100 ~mol/ml, preferably 1-20 ~mol/ml, x-ray-opacifying agents are used in the range of 3-100 mg of opacifying elements (e.g., iodine, iron, etc.)/ml and ultrasonic-opacifying preparations in the range of 0.01 to 50 ~l of gas/ml, preferably 0.1 to 5 ~l of gas/ml.
Magnetites are also used as aqueous solutions with about 0.1 ~mol of iron/ml to 500 ~mol of iron/ml. Strongly colored solutions with about 20-500 ~mol of iron/ml are preferred.
Metalloporphyrins are used in the same concentration range (0.1 ~mol/ml - 500 ~mol/ml), whereby the preferred range is approximately 20-200 ~mol/ml.
Other paramagnetic or metal ion-containing or iodine-containing dyes, such as, e.g., Bengal pink, erythrosin, tetrachlorotetraiodine fluorescein, are preferably used at somewhat higher concentrations (50-500 ~mol/ml).
The above-indicated concentrations are to be considered as guideline values; individual cases may exceed or fall below these guideline values. They are sufficient to produce a clear imaging effect and at the same time a visually discernible marking of the tissue in the respective radiological process.
The following examples are used to explain the object of the invention, without intending that they be limited to this object.
21 826(`3~-~
Example 1 Marking of a Biopsy Area with Magnetites A suspect tissue region is identified in MRT. To study tumorous tissue, a needle biopsy is performed, in which cells are obtained from the corresponding area. To control the exact position of the needle as well as to facilitate finding the appropriate tissue region again in the case of a subsequent operation, 0.5 ml of a 50 mmol dextran-magnetite solution (SH U
555, Schering AG, Berlin) is injected. After the solution is injected, the appropriate area in the MRT represents a signal alarm. In the laying-open during surgery, the biopsy area can be discerned from the brownish discoloration. In the same way, the pathologist can get his bearings in the surgery and apply the necessary sections in the proper plane.
Example 2 Marking of a 8iopsy Area with Porphyrins The procedure is as described in Example 1. As a marking solution, however, 2 ~mol of manganese (as manganese(III) {tetrakis-[3-(carboxylatomethoxy)-phenyl]-porphyrin}-acetate complex) is injected in a milliliter of physiological common salt solution. In the laying-open during surgery, the biopsy area can be discerned from the yellow-greenish discoloration. The color effect can be additionally enhanced by short-term stimulation with W light.
Example 3 Marking of a Breast Cancer with Magnetites During mammography, microcalcifications are found at a volume of less than 0.5 cm3. The region is stereotactically biopsied. At the same time, 0.2 ml of 500 mmol magnetite solution is injected. The biopsy reveals a breast cancer. The identification of the lesion during surgery is facilitated by the clear black-brown discoloration.
Example 4 Marking of Muscle Tissue with Magnetites The dextran-magnetite solution (SH U 555, Schering AG) is injected at a concentration of A) 500 mmol of Fe/liter, B) 250 mmol of Fe/liter, C) 125 mmol of Fe/liter and a dose of 1 ml in muscle tissue and examined by computer tomography. The magnetite depot is clearly discernible in all cases and strictly limited in shape. After the corresponding tissue region is laid open, the magnetite is optically readily discernible from the brownish discoloration.
Example 5 Methylene blue-containing microparticles that consist of poly(D,L-lactic acid-glycolic acid) are irradiated in vitro in a tissue sample with ultrasound (sonic pressure > 50 dB, frequency 2.5 Mhz), and in this process methylene blue is released in the tissue.
The methylene blue-containing particles can be produced as disclosed in DE 43 30 958 (Example 8), by 4 g of poly(D,L-lactic acid-glycolic acid) (50:50) (Resomer RG 503, Boehringer Ingelheim), dissolved in 50 ml of CH2Cl2, being emulsified with 20 mg of methylene blue, dissolved in 4 ml of aqueous 4% gelatin solution, while being stirred with a fast stirrer. Then, another 21 826~6 200 ml of a 4% autoclaved gelatin solution is added. The emulsion is stirred for 8 hours at room temperature. The particles that are produced are filtered by a 5 ~m filter, separated by centrifuging, resuspended in S0 ml of 4% autoclaved gelatin solution, frozen at -78C, and freeze-dried. After resuspension, the gaseous microparticles are separated by centrifuging (at 1000 rpm, 30 min). The particles thus obtained are taken up in 20 ml of water for injection purposes and can be used directly for marking bodily tissue.
Ex~mple 6 0.05 ml of a suspension of gas-filled hollow bodies with a shell made of biodegradable poly-2-cyanoacrylic acid butyl ester (W093/25242; Example 1) and an average particle size of about 2 ~m is injected into the musculature of the upper leg of a dog.
3.5 hours later, a strictly limited depot of contrast medium, which can be readily located in all planes, is found in the ultrasonic study with a 3.5 MHz transducer.
Claims (10)
1. Use of colored NMR or x-ray contrast media or of dye-containing ultrasonic contrast media for the production of a diagnostic agent for visually marking bodily tissues.
2. Use of ultrasonic contrast media for the production of a diagnostic agent for marking bodily tissues.
3. Use of an agent according to claim 1 that contains as a colored NMR contrast medium at least one metal porphyrin, magnetic iron oxide particles, nitroxide or melanin.
4. Use of an agent according to claim 1 that contains as a colored x-ray contrast medium Bengal pink, erythrosin or tetrachlorotetraiodine fluorescein.
5. Use of an agent according to claim 1 that contains as a dye-containing ultrasonic contrast medium microparticles that consist of a shell made of a biodegradable polymer and a gaseous and dye-containing nucleus.
6. Use of an agent according to claim 2 that contains as an ultrasonic contrast medium microparticles that consist of a polylactide-glycolide or polycyanacrylate shell and a gaseous nucleus.
7. Agents for visually marking bodily tissues that contain at least one colored, radiologically detectable substance.
8. Agents for marking bodily tissues according to claim 7 that contain magnetites as a colored, radiologically detectable substance.
9. Agents for marking bodily tissues according to claim 7 that contain metal complexes of porphyrins as a colored, radiologically detectable substance.
10. Agents for marking bodily tissues according to claim 7 that contain gas-containing microparticles, which optionally additionally contain a dye, as a colored, radiologically detectable substance.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4403789.9 | 1994-02-03 | ||
DE4403789A DE4403789A1 (en) | 1994-02-03 | 1994-02-03 | Means for visually marking body tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2182686A1 true CA2182686A1 (en) | 1995-08-10 |
Family
ID=6509687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002182686A Abandoned CA2182686A1 (en) | 1994-02-03 | 1995-01-13 | Agent for marking bodily tissues |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0742724A1 (en) |
JP (1) | JPH09508397A (en) |
CA (1) | CA2182686A1 (en) |
DE (1) | DE4403789A1 (en) |
WO (1) | WO1995020981A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656450B2 (en) | 2000-07-17 | 2003-12-02 | California Institute Of Technology, Inc. | Macrocyclic magnetic resonance imaging contrast agents |
US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
US6713046B1 (en) | 1997-10-27 | 2004-03-30 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
US6770261B2 (en) | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US7029655B2 (en) | 2000-10-04 | 2006-04-18 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
US7354568B1 (en) | 1997-10-27 | 2008-04-08 | California Institute Of Technology | Magnetic resonance imaging agents for the detection of physiological agents |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1304085A3 (en) | 1994-09-16 | 2004-01-21 | Ethicon Endo-Surgery, Inc. | Biodegradable tissue marking device |
US5900228A (en) | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
US6493570B1 (en) * | 1998-11-02 | 2002-12-10 | Photogen, Inc. | Method for improved imaging and photodynamic therapy |
US6022526A (en) * | 1997-07-30 | 2000-02-08 | Pharmacyclics, Inc. | Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma |
US6270464B1 (en) | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
US6986740B2 (en) | 1998-11-02 | 2006-01-17 | Xantech Pharmaceuticals, Inc. | Ultrasound contrast using halogenated xanthenes |
US6356782B1 (en) | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
DE19925311B4 (en) | 1999-05-27 | 2004-06-09 | Schering Ag | Multi-stage process for the production of gas-filled microcapsules |
ITMO20010060A1 (en) * | 2001-03-30 | 2002-09-30 | H S Hospital Service S R L | METHOD AND MEANS FOR THE IDENTIFICATION AND REPORTING OF A NON-PALPABLE INJURY IN SOFT FABRICS |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3827940A1 (en) * | 1988-08-13 | 1990-03-01 | Schering Ag | 13,17-PROPIONIC ACID AND PROPIONIC ACID DERIVATIVE SUBSTITUTED PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
-
1994
- 1994-02-03 DE DE4403789A patent/DE4403789A1/en not_active Withdrawn
-
1995
- 1995-01-13 WO PCT/EP1995/000123 patent/WO1995020981A1/en not_active Application Discontinuation
- 1995-01-13 JP JP7520342A patent/JPH09508397A/en active Pending
- 1995-01-13 CA CA002182686A patent/CA2182686A1/en not_active Abandoned
- 1995-01-13 EP EP95906937A patent/EP0742724A1/en not_active Withdrawn
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770261B2 (en) | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US6713046B1 (en) | 1997-10-27 | 2004-03-30 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
US7354568B1 (en) | 1997-10-27 | 2008-04-08 | California Institute Of Technology | Magnetic resonance imaging agents for the detection of physiological agents |
US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
US6656450B2 (en) | 2000-07-17 | 2003-12-02 | California Institute Of Technology, Inc. | Macrocyclic magnetic resonance imaging contrast agents |
US7029655B2 (en) | 2000-10-04 | 2006-04-18 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
Also Published As
Publication number | Publication date |
---|---|
JPH09508397A (en) | 1997-08-26 |
EP0742724A1 (en) | 1996-11-20 |
WO1995020981A1 (en) | 1995-08-10 |
DE4403789A1 (en) | 1995-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2182686A1 (en) | Agent for marking bodily tissues | |
CA2361530C (en) | Methods and chemical preparations for time-limited marking of biopsy sites | |
US20090285760A1 (en) | Method for detecting cancer using icg fluorescence method | |
EP0194644B1 (en) | Biodegradable microspheres and method for their preparation | |
CN108472373A (en) | Biological degradability tumour sealant | |
CN109395101A (en) | Target the preparation method of the mr contrast agent of blood-brain barrier and glioma | |
WO2005067982A2 (en) | Methods for imaging the lymphatic system using dendrimer-based contrast agents | |
WO2014035620A1 (en) | Contrast imaging applications for lanthanide nanoparticles | |
US11730831B2 (en) | Imaging agents and methods of using the same | |
CA2433956A1 (en) | Use of mri to screen individuals for prostate cancer | |
CN105327365B (en) | A kind of magneto-optic bimodal imaging nano-probe and its application | |
CN108827877A (en) | A kind of Ratio-type nanometer photo-acoustic detection probe and the preparation method and application thereof | |
WO2005017539A2 (en) | Imaging pathology | |
AU2014229811B2 (en) | Hypoosmotic solutions for lymph node detection | |
EP1181570B1 (en) | Method of magnetic resonance imaging | |
JP2013135801A (en) | Diagnostic imaging apparatus visualizing inside of sentinel lymph node, and method for operating the same | |
Hegazy et al. | Diagnostic Significance of Fine Needle Biopsy and Cell Block in Skin and Subcutaneous Nodules | |
RU2761827C1 (en) | Means and method for combined contrast enhanced magnetic resonance imaging image visualization of biomechanics of the processes of infiltration, invasion and metastasis of malignant cells | |
US20040162479A1 (en) | Percutaneous removal of sentinel lymph node using contrast imaging for identification | |
Asaki et al. | Diagnosis of submucosal tumors by injecting a water soluble contrast medium: Basic research and imaging of tumors | |
Yeung et al. | Feasibility and safety of silicone rubber contrast-enhanced microcomputed tomography in evaluating the angioarchitecture of prostatectomy specimens | |
CN109675063A (en) | Target the preparation method of the mr contrast agent of Epileptic focus region P- glycoprotein | |
CN117503958A (en) | Method for preparing controllable target spot in isolated living pig liver by iodized oil-biological glue mixed preparation | |
CN114601938A (en) | Fluorescence/nuclear magnetic probe for guiding breast cancer breast-protecting incisal edge accurate evaluation | |
CN112891565A (en) | Application of zinc-lutidine amine in preparing medicine for diagnosing thrombotic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |